Skip to main content
. 2022 Mar 23;13:1639. doi: 10.1038/s41467-022-29301-9

Table 3.

Number (%) of safety events in the 21 days following second dose, according to vaccination schedule.

Heterologous Homologous
1:1 matching 1:2 matching 1:5 matching 1:1 matching 1:2 matching 1:5 matching
N participants 14,325 12,512 8569 14,325 25,024 42,845
N (%) of venous thromboembolism events 1 1 1 0 0 0
N (%) of venous thromboembolism with thrombocytopenia 1 1 1 0 0 0
N (%) of myopericarditis 0 0 0 0 0 1